Inhibrx Biosciences, Inc.
$82.39
▼
-5.25%
2026-04-21 07:30:01
inhibrx.com
NMS: INBX
Explore Inhibrx Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.29 B
Current Price
$82.39
52W High / Low
$94.56 / $10.84
Stock P/E
—
Book Value
$0.55
Dividend Yield
—
ROCE
-119.83%
ROE
-1.98%
Face Value
—
EPS
$-9.04
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
109
Beta
—
Debt / Equity
1,338.82
Current Ratio
3.93
Quick Ratio
3.93
Forward P/E
-26.98
Price / Sales
845.75
Enterprise Value
$1.08 B
EV / EBITDA
-8.16
EV / Revenue
832.51
Rating
Buy
Target Price
$150
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Assembly Biosciences, Inc. | $28.13 | — | $446.22 M | — | -5.8% | -5.1% | $39.7 / $9.68 | $13.04 |
| 2. | Moleculin Biotech, Inc. | $2.56 | — | $13.66 M | — | -164.37% | -2.56% | $28.61 / $1.79 | $4.69 |
| 3. | Enlivex Ltd. | $0.88 | — | $207.92 M | — | -0.65% | 1.26% | $2.1 / $0.66 | $8.15 |
| 4. | Damora Therapeutics, Inc. | $26.43 | — | $1.6 B | — | -87.69% | -1.64% | $29.22 / $16.5 | $-110.11 |
| 5. | Soleno Therapeutics, Inc. | $52.67 | 130.16 | $2.72 B | — | 2.98% | 6.01% | $90.32 / $29.43 | $8.61 |
| 6. | Cytokinetics, Incorporated | $65.05 | — | $8.11 B | — | -50.1% | 197.47% | $70.98 / $29.31 | $-5.37 |
| 7. | Zevra Therapeutics, Inc. | $10.78 | 7.23 | $601.51 M | — | -1.72% | 85.66% | $13.16 / $6.85 | $2.72 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 1.3 M | 0 M | 0.1 M | — |
| Operating Profit | -30.92 M | -33.81 M | -27.39 M | -42.9 M | -49.93 M | — |
| Net Profit | -32.83 M | -35.26 M | -28.65 M | -43.31 M | -47.87 M | — |
| EPS in Rs | -2.25 | -2.41 | -1.96 | -2.97 | -3.28 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.3 M | 0.2 M | 1.8 M | 1.3 M |
| Operating Profit | -135.03 M | -331.45 M | -219.22 M | -115.32 M |
| Net Profit | -140.06 M | 1.69 B | -241.36 M | -115.33 M |
| EPS in Rs | -9.59 | 115.53 | -16.52 | -7.9 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 146.48 M | 180.77 M | 307.89 M | 16.64 M |
| Total Liabilities | 138.49 M | 47.18 M | 264.39 M | 23.95 M |
| Equity | 7.99 M | 133.58 M | 43.5 M | -7.3 M |
| Current Assets | 132.83 M | 160.4 M | 295.36 M | 6.26 M |
| Current Liabilities | 33.8 M | 40.73 M | 56.31 M | 20.77 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -129.79 M | -194.41 M | -193.31 M | -90.81 M |
| Investing CF | -0.03 M | -2.6 M | -4.59 M | -0.69 M |
| Financing CF | 101.45 M | 71.68 M | 201.96 M | 91.5 M |
| Free CF | -129.82 M | -197.01 M | -197.9 M | -91.5 M |
| Capex | -0.03 M | -2.6 M | -4.59 M | -0.69 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 550% | -88.89% | 38.36% | — |
| Earnings Growth % | -108.3% | 799.19% | -109.29% | — |
| Profit Margin % | -10773.46% | 843786% | -13408.94% | -8864.34% |
| Operating Margin % | -10386.54% | -165724% | -12178.94% | -8864.18% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -9644.15% | 851675% | -11482.94% | -8770.02% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.